期刊文献+

肝癌射频消融术对外周血Th1和Th2细胞因子的影响 被引量:11

The effect of radiofrequency ablation on the level of plasma Th1/Th2 cytokines in hepatocellular carcinoma
下载PDF
导出
摘要 目的研究射频消融治疗对原发性肝癌(HCC)患者外周血中Th1、Th2细胞因子的影响。方法采集30例HCC患者射频消融前和射频消融后3或7 d和肝癌复发时的血浆,用液相芯片检测Th1、Th2细胞因子水平的变化。结果射频消融后Th1型细胞因子干扰素-γ(IFN-γ)和白细胞介素-12p40(IL-12p40)水平较消融前明显增加[IFN-γ:(101.30±78.70)pg/ml vs.(55.70±36.20)pg/ml;IL-12p40:(57.70±31.90)pg/ml vs.(18.10±16.70)pg/ml;P均<0.05)。但肝癌复发后IFN-γ和IL-12p40水平比消融后的水平明显下降[IFN-γ:(56.50±41.70)pg/ml vs.(101.30±78.70)pg/ml;IL-12p40:(18.90±16.460)pg/ml vs.(57.70±31.90)pg/ml;P均<0.05),与消融前比较无明显差异。射频消融治疗前后,Th2型细胞因子IL-4和IL-6水平未出现明显变化[IL-4:(11.33±12.70)pg/ml vs.(13.31±15.56)pg/ml;IL-6:(17.86±22.93)pg/ml vs.(24.46±28.46)pg/ml]。射频消融治疗后,Th2型细胞因子水平下降者伴随较长的复发时间间隔[(14.00±4.35)月],而Th2细胞因子水平增高的患者复发时间则相对较短[(5.06±4.26)月]。结论射频消融可短期激活Th1型免疫反应,但激活的Th1型免疫反应不能预防肝癌的复发。Th2型细胞因子水平改变与肝癌复发时间有关,监测Th2型细胞因子水平变化可能有助于预测肝癌复发。 Objective To study the effect of radiofrequency ablation(RFA) on plasma Th1/Th2 cytokines in hepatocellualr carcinoma(HCC) patients. Methods Thirty HCC patients' plasma were collected before RFA(time zero), 3or 7days(3/7) after RFA,and at the time point of HCC recurrence. Liquid chip was used to detect the levels of Th1/Th2 cytokines. Results After RFA treatment, the levels of plasma interferon-γ(IFN-γ) and interleukin-12p40(IL-12p40) significantly increased compared with the time zero [IFN-γ:(101.30±78.70)pg/ml vs.(55.70±36.20)pg/ml;IL-12p40:(57.70±31.90)pg/ml vs.(18.10 ±16.70)pg/ml, P〈0.05)]. When HCC recurrence happened, the levels of plasma IFN-γ and IL-12p40 decreased compared with the level of 3/7 days after RFA[IFN-γ:(56.50±41.70)pg/ml vs.(101.30±78.70)pg/ml;IL-12p40:(18.90±16.46)pg/ml vs.(57.70±31.90)pg/ml; P〈0.05) and had no significant change compared with time zero.Compared with time zero, the level of plasma interleukin-4(IL-4) and IL-6 had no significant changes at time 3/7 days[time zero vs. time 3/7 days,IL-4:(11.33±12.70)pg/ml vs.(13.31±15.56)pg/ml;IL-6:(17.86±22.93) vs.(24.46±28.46)pg/ml].However, through analyzing the relation between the change of individual Th2 cytokines and individual recurrent time,the patients with decreased Th2 cytokines were associated with a longer interval time span of HCC recurrence [(14.00 ±4.35)months], and the patients with increased Th2 cytokines were associated with a shorter time spaninterval of HCC recur-rence[(5.06±4.26)months]. Conclusion RFA can shortly activate Th1 response; however, the activated Th1 response can not prevent HCC recurrence.The level of Th2 cytokines is related to the time of recurrence. The detection of level of Th2 cytokine is beneficial for early warning HCC recurrence.
出处 《北京医学》 CAS 2014年第9期728-731,共4页 Beijing Medical Journal
基金 国家自然科学基金(81272266 81361120401) 国家科技支撑计划(2012BAI15B08)
关键词 肝细胞癌 射频消融 TH1 TH2型细胞因子 Hepatocellular carcinoma(HCC) Radiofrequency ablation(RFA) Th1/Th2 cytokines
  • 相关文献

参考文献16

  • 1李亚松,曹建彪,姜胜莹.原发性肝癌射频消融治疗研究进展[J].北京医学,2013,35(9):796-798. 被引量:10
  • 2扈彩霞,郑加生,钱智玲,崔石昌,朱桐.原发性肝癌患者射频消融前后外周血T淋巴细胞绝对值变化的临床意义[J].北京医学,2011,33(6):451-453. 被引量:14
  • 3Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: lO-year outcome and prognostic factors [J]. Am J Gastroenterol, 2012, 107:569-577.
  • 4Lippitz BE. Cytokine patterns in patients with cancer: a systematicreview[J]. Lancet Oncol, 2013, 14:e218-228.
  • 5Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepate- ctomy for small hepatellular carcinoma[J]. Ann Surg, 2006, 243: 321-328.
  • 6Huo TI, Huang YH, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and fixture perspectives [J]. J Chin Med Assoc, 2005, 68:155-159.
  • 7Lam VW, Ng KK, Chok KS, et al. Incomplete ablation after ra- diofrequency ablation of bepatocellular carcinoma: analysis of risk factors and prognostic factors [J]. Ann Surg Oncol, 2008, 15:782-790.
  • 8Rant CP, Izzo F, Marra P, et al. Significant long-term survival af- ter radiofrequency ablation of unresectable hepatocellular carcino- ma in patients with cirrhosis [J]. Ann Surg Oncol, 2005, 12: 616-628.
  • 9Machi J, Bueno RS, Wong LL. Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hep- atocellular carcinoma[J]. World J Surg, 2005, 29:1364-1373.
  • 10Vivarelli M, Gugliehni A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver [J]. Ann Surg, 2004, 240:102-107.

二级参考文献25

  • 1吕俊宏,王远东.全身热疗对机体抗肿瘤免疫的影响[J].国际肿瘤学杂志,2006,33(4):270-273. 被引量:11
  • 2Zerbini A, Pilli M, Fagnoni F, et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency therma ablation. J Immunother,2008,31:271-282.
  • 3Ali MY, Grimm CF, Ritter M, et al. Activation ofdendritic cells by local ablation ofhepatocellular carcinoma. J Hepato,2005,43: 817-822.
  • 4Napoletano C, Taurino F, Biffoni M, et al. RFA stronglymodulates the immune system and anti -tumor immune responses in metastatic liver patients. Int J Onco,2008,32:481-490.
  • 5Sehueller G, Stift A, Friedl J, et al. Hyperthermia improves cellular immune response to human hepatocelluar carcinoma subsequent to coculturewith tumor lysate pulsed dendritic ceils. Int J Onco,2003,22:1397-1402.
  • 6Livraghi T. Single HCC smaller than 2 ern: surgery or ablation: interventional oncologist's perspective. J Hepatobiliary Pancreat Sci,2010,17:425-429.
  • 7Kudo M. Radiofrequency ablation for hepatocelluar carcinoma : updated review in 2010. Oncology,2010,78:113-124.
  • 8Liu JG, Wang Yl, Du Z. Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis. World J Gas?troenterol,20 I 0, 16:3450-3456.
  • 9Hung HH, Chiou YY, Hsia CY, et al. Survival rates are compara?ble after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol,2011,9:79- 86.
  • 10Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequen?cy ablation for hepatocellular carcinoma. An analysis of 1000 cas?es. Cancer,2005,103:1201-1209.

共引文献20

同被引文献97

引证文献11

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部